surmount-1 tirzepatide trial weight loss non-diabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes Tirzepatide's Surmount-4 Trial Reveals Groundbreaking

As powerful anti-obesity drugs become more widely available, companies are repositioning themselves with new products and services.

Dean Jones, DC, a holistic obesity expert dedicated to helping people achieve sustainable weight loss and graduate to medication independence

French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and weight control drug semaglutide to just once a month, according researchpresented at this year's annual meeting of the European Association for the Study of Diabetes (EASD)."Glucagon-like peptide-1 agonist (GLP-1) drugs have transformed type 2 diabetes care, but weekly injections can be burdensome for patients, said lead author, Dr Claire Mgret from Adocia, Lyon, France, the

Hence, in a world where appetite and the desire to eat are reduced, there is the potential for lost sales of fast foods, snacks and sugary drinks